ESG is a cost-effective treatment option for people living with obesity and should be considered in commercial health plans as an additional treatment option for clinically eligible patients.
Keyphrases
- randomized controlled trial
- metabolic syndrome
- weight loss
- insulin resistance
- end stage renal disease
- type diabetes
- healthcare
- public health
- newly diagnosed
- cardiovascular disease
- chronic kidney disease
- weight gain
- peritoneal dialysis
- prognostic factors
- high fat diet induced
- ultrasound guided
- clinical trial
- skeletal muscle
- replacement therapy
- climate change
- human health
- social media
- double blind